Investigating the relationship between melatonin levels, melatonin system, microbiota composition and bipolar disorder psychopathology across the different phases of the disease.
Mirko ManchiaAlessio SquassinaClaudia PisanuDonatella CongiuMario GarzilliBeatrice GuisoFederico SupraniPasquale ParibelloVittoria PulcinelliMaria Novella IaselliFederica PinnaFlavia ValtortaBernardo CarpinielloStefano ComaiPublished in: International journal of bipolar disorders (2019)
In this cross sectional (case-control vs. BD comparisons) and longitudinal (24 months) study, we expect to clarify the link between the MLT system, microbiota and BD psychopathology. We expect to identify some typical BD symptomatic clusters that will be more strictly associated with variations in the MLT system. In a personalized medicine perspective, this subgroup of BD patients may benefit from a pharmacological therapy targeting the MLT system. Trial registration This study protocol was approved by the Ethics Committee of the University Hospital Agency of Cagliari (PG/2019/6277).
Keyphrases
- bipolar disorder
- study protocol
- cross sectional
- end stage renal disease
- case control
- randomized controlled trial
- ejection fraction
- clinical trial
- phase iii
- public health
- chronic kidney disease
- newly diagnosed
- major depressive disorder
- peritoneal dialysis
- prognostic factors
- open label
- bone marrow
- stem cells
- mesenchymal stem cells
- drug delivery
- patient reported
- smoking cessation
- double blind
- global health
- placebo controlled